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PercutaneousBackground/objectives: Catheter-based renal denervation for the treatment of drug-resistant hypertension has
been intensively investigated in recent years. To date, only limited data have been published using multi-
electrode radiofrequency ablation systems that can deliver lesions with a pre-determined pattern. This study
was designed to evaluate the safety and efﬁcacy of the next generation EnligHTN™ renal denervation system.
Six-month primary endpoint data are presented here.
Methods: We conducted this ﬁrst-in-human, prospective, multi-center, non-randomized study in 39 patients
(62% male, mean age 63 years, and mean baseline ofﬁce blood pressure 174/93 mm Hg) with drug-resistant
hypertension. The primary safety and efﬁcacy objectives were to characterize, from baseline to 6 months post-
procedure, the rate of serious procedural and device related adverse events, as adjudicated by an independent
Clinical Events Committee, and the reduction of ofﬁce systolic blood pressure.
Results: Renal artery denervation, using the next generation EnligHTN multi-electrode system signiﬁcantly
reduced ofﬁce blood pressure from baseline to 1, 3, and 6months by−19/7,−26/9 and−25/7 mmHg, respec-
tively (P ≤ 0.0005). No serious device or procedure related adverse events affecting the renal arteries or renal
function occurred through.
Conclusions: Renal sympathetic denervation using the next generation EnligHTN renal denervation system
resulted in safe, rapid, and signiﬁcantmeanofﬁce blood pressure reduction thatwas sustained through6months.
Future studies will need to address the utility of this system against an appropriate placebo based comparator.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Background/objectives
Hypertension is the leading attributable risk factor for cardiovascular
morbidity and mortality around the world [1–3]. Resistant hyperten-
sion, as deﬁned by the inability to achieve target blood pressure despite
three or more antihypertensive agents remains a treatment dilemma,
with an incidence of between 10 and 12% [4,5]. Furthermore, this
group of patients has a three fold increased risk of cardiovascular events
over the group of patients with hypertension that is treated to target
blood pressures [3].epartment of Medicine, North
.G. Worthley).
. This is an open access article underA number of novel device based therapies are emergingwith the po-
tential to improve blood pressure in patients with treatment resistant
hypertension [6–8]. The most studied of these remains catheter based
radiofrequency renal artery denervation. Initial observational trials
showed this therapy to be associated with approximately a 25 mm Hg
BP reduction at 6 months in resistant hypertension patients and led to
a consensus opinion for clinical appropriateness in treatment resistant
hypertension [8–11]. Controversy now exists over the incremental
value of this technology with the recent SYMPLICITY HTN-3 trial failing
to meet its primary efﬁcacy endpoint versus sham control [12]. How-
ever, this technology utilized a ﬁrst generation single-tip electrode
radiofrequency ablation catheter that requires signiﬁcant operator ma-
nipulation with point by point ablation. Therefore, there is a higher risk
of producing an inadequate ideal geometric distribution of lesions in the
renal artery. Furthermore, fewer lesions were created in trials of thethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. The EnligHTN generation 2 renal denervation system, consisting of the EnligHTN
renal artery guide catheter, EnligHTN renal artery ablation catheter, and next generation
EnligHTN RF ablation generator.
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ship with BP reduction. In fact, a SYMPLICITY HTN-3 subgroup analysis
showed that more robust response was related to more lesions and
four-quadrant positioning [16].
The EnligHTN renal denervation system has a multi-electrode plat-
form with a predeﬁned geometric orientation facilitating a more favor-
able lesion creation pattern for the purpose of interrupting renal artery
nerve trafﬁc [7]. The system can be positioned once and deliver four
lesions prior to movement. The EnligHTN I Study, a multicenter, ﬁrst-
in-human observation safety and efﬁcacy study utilizing the ﬁrst gener-
ation EnligHTN renal denervation system (St. Jude Medical, MN, USA),
reported a 26 mm Hg reduction in ofﬁce systolic BP at the 6 month pri-
mary endpoint [9]. However, theﬁrst generation of this system required
each electrode to deliver therapy sequentially, and therefore the proce-
durewas time consuming. The next generation EnligHTN system allows
for simultaneous delivery of all four electrodes and includes modiﬁca-
tions in the temperature, including rate of rise over time and duration,
based on extensive preclinical testing, to optimize renal artery lesion
creation. The EnligHTN III trial was designed to allow comparisons to
be made with the ﬁrst generation, and therefore test both the safety
and efﬁcacy of this next generation system. We present the primary
endpoint, the 6-month safety and efﬁcacy data from the multicenter,
ﬁrst-in-human EnligHTN III trial.
2. Methods
2.1. Study population
Patients from 18 to 80 years of age who had been referred for man-
agement of resistant HTN by a primary healthcare practitioner or spe-
cialist at six participating centers (4 in Australia and 2 in New
Zealand) were screened for participation. The protocol was based on
the previously published EnligHTN I trial [9]. In brief, patients needed
to have an ofﬁce Systolic BP that remained ≥160mmHgdespite the sta-
ble use of ≥3 anti-hypertensive medications concurrently at maximally
tolerated doses. At least one of the anti-hypertensive medications was
required to be a diuretic, unless there was documented intolerance. Pa-
tients also had to have a mean daytime systolic Ambulatory BP
N135 mm Hg. In all participating patients the anti-hypertensive drug
regimenwas to remain stable for aminimumof 14 days prior to thepro-
cedure and through the 6-month follow-up.
2.2. Study design
The EnligHTN III study is a ﬁrst-in-human, prospective, multi-center,
non-randomized study to evaluate safety and efﬁcacy of a new genera-
tor and algorithm with the same multi-electrode catheter used in the
EnligHTN I trial, allowing simultaneous delivery of therapy from all
four electrodes, for the purpose of renal artery sympathetic denervation
in patients with drug-resistant hypertension. The primary safety objec-
tivewas to characterize the rate of serious procedural and device related
adverse events from date of procedure through 6 months post-proce-
dure, as adjudicated by a Clinical Events Committee (CEC). The primary
efﬁcacy objective was the reduction of ofﬁce systolic BP at 6 months
post-procedure as compared to baseline. Study patients will continue
follow-up at 1, 3, 6, 12, 18, and 24 months post-denervation procedure.
The study was approved by each institution's Research Ethics Commit-
tee and is registered with Clinical Trials Registry (Registration No.
NCT01836146). The trial is sponsored by St. Jude Medical, St. Paul,
Minnesota, USA.
2.3. Baseline study procedures
Following written informed consent, medical history and physical
examination including ofﬁce BP were completed. The ofﬁce BP was col-
lected according to the Standard Joint National Committee VIIGuidelines and ESC/ESH Guidelines [14,15]. Each center and each en-
rolled patient was provided with an Automatic BP Monitor (Omron
Healthcare, Inc. Bannockburn, Illinois, USA) for collection of ofﬁce and
home BP values. All patients recorded home BP values for seven days
(three readings in the morning and three readings in the evening),
anti-hypertensive medication regimen daily for a minimum of 14 days
and completed a 24-h Ambulatory BP assessment. The 24-h Ambulatory
BP was obtained by using an Ambulatory Blood Pressure System
(Spacelabs Healthcare, Inc. Issaquah, Washington, USA).
After the 14 day screening period, all patients returned to their re-
spective study center to complete the baseline assessment. Blood and
urine were collected for Complete Blood Count, Basic Metabolic Proﬁle,
SerumCreatinine, EstimatedGlomerular FiltrationRate (eGFR), Cystatin
C, and Urine Albumin to Creatinine ratio. An Ofﬁce BP assessment using
the BPmonitor, ofﬁce heart rate, quality of life questionnaire, a renal ar-
tery CT scan, and a review of medication logs were also performed.
Qualifying patients were scheduled for the renal denervation procedure
within the following 30 days.
2.4. The next generation EnligHTN renal denervation system
The St. Jude Medical EnligHTN™ renal denervation system used in
this study consists of the next generation EnligHTN radiofrequency gen-
erator, the EnligHTN renal artery ablation catheter, and the EnligHTN
renal artery guide catheter (Fig. 1). The generator utilizes a novel algo-
rithm for the delivery of 60 s of radiofrequency energy, optimized for si-
multaneous delivery of therapy through all 4 electrodes. There is a two-
stage rate of temperature rise with an initial rate of 4 °C/s, reducing to
1 °C/s between 65 and 70 °C. Preclinical studies show that the next gen-
eration generator with the updated algorithm delivers reproducible le-
sions consistent with preclinical data from the ﬁrst generation system.
The next generation generator also uses a proprietary algorithm de-
scribed as Adaptive Control. Adaptive Control modulates the power
and temperature to minimize interrupted ablation errors that may
have caused electrode shut-offs with the ﬁrst generation system. If the
generator senses rapid impedance or temperature change indicating in-
stability, it will respond by modulating the power. This is sometimes
caused by patient discomfort/movement or heavy breathing and can
bemanagedwith the Adaptive Controlmodulation. Themaximum tem-
perature is now 70 °C and is administered for 60 s. Once again, these are
based on extensive preclinical testing showing that the created lesions
are consistent with the ﬁrst generation system.
Importantly, this system utilizes a diagnostic mode, in order to en-
sure good electrode contact and thus provides a predictor of adequate
lesion creation. In brief, approximately 0.5 W of radiofrequency energy
is delivered to all electrodes simultaneously which should induce a 2 °C
or greater temperature rise in each electrode. If this is not achieved, then
Fig. 2. Diagram demonstrating predictable, circumferential renal artery lesion pattern
creation from the EnligHTN renal denervation system.
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pose the electrode to the vessel wall and re-test. The generator allows
for up to 5 min of continuous delivery of 0.5 W of radiofrequency ener-
gy, which has failed to induce any vascular injury in preclinical models,
attesting to the safety of this diagnostic mode.
The generator with this system comes with an interactive, intuitive
user interface which simultaneously displays temperature, impedance
and power for all four electrodes. Thus the results of temperature rise,
impedance change and power modulation can be monitored continu-
ously throughout both the diagnostic phase, as well as during therapy
delivery. Furthermore, should adequate temperature rise to create an
appropriate lesion not occur, as deﬁned by the inability to achieve a
temperature of at least 50 °C by 20 s, then the electrode can be
deactivated by a simple touch screen command. Then, that electrode's
position can be slightly manipulated and re-application of therapy at
that single location can be performed. This is done by simple touch
screen activation and deactivation of electrodes prior to therapy deliv-
ery (Fig. 2).2.5. Renal denervation procedure
Patientswere taken to the Catheterization Laboratory toundergo the
renal denervation procedure, as previously published, using conscious
sedation. Images of the left and right main renal arteries were recorded
using non-ionic contrast and the diameter and length of each of the
main renal arteriesmeasured. The renal denervation basket sizewasde-
termined from the renal artery diameter (small basket 4.0–5.5 mm di-
ameter/large basket 5.5–8.0 mm diameter) and the renal denervation
catheterwas inserted such that the catheter's tipwas proximal to the bi-
furcation of one of the main renal arteries. The basket on the catheter
was then opened with the impedance of each electrode on the basket
monitored in diagnostic mode.
Renal artery denervation was commenced and performed simulta-
neously by all four electrodes with the impedance, temperature and
RF energy delivery monitored, as explained earlier. The basket was
then collapsed and pulled back proximally approximately 1 cm to
avoid lesion overlap. The basket was rotated approximately 45° and
then expanded. Placement was conﬁrmed under ﬂuoroscopy and the
ablation procedure was repeated. In general, 8 ablations were delivered
per renal artery to achieve circumferential ablation. Images of the renal
artery were taken using non-ionic contrast and checked for signs of
renal artery irregularities (i.e., vasospasm, stenosis or dissection). The
renal artery ablation procedure was then repeated for the other renal
artery and the catheter was withdrawn. Finally, the sheath was re-
moved and hemostasis achieved according to each center's standardof care. Procedural datawere recorded for each patient, including proce-
dure duration and number of ablations delivered.
2.6. Post-procedure and pre-discharge
Upon completion of the renal denervation procedure, the patient
was moved to a recovery area and vital signs were monitored continu-
ously. BP was measured every 15 min during the ﬁrst 2 h post-
procedure and then in 4-h intervals when the subject was awake until
discharge. Patients were discharged from the hospital on the following
day if medically stable.
2.7. Follow-up
Patients underwent the following during the post-discharge visits:
ofﬁce BP assessment, review of medications, blood and urine collection,
24-h Ambulatory BP assessment, home BP monitoring and physical as-
sessment. Patients were scheduled for follow-up visits at 1, 3, and 6
months (Primary Objective) post-procedure and will continue being
followed per study protocol at 12, 18, and 24 months post-procedure.
Renal artery imaging by CT or duplex ultrasound was completed at
the 6-month follow-up visit. Renal artery evaluation during other
follow-up visits was performed if clinically indicated.
2.8. Study objectives
The primary efﬁcacy objective was reduction of ofﬁce BP from base-
line to 6 months, which was measured according to guidelines at all
follow-up visits. Additional efﬁcacy data collection included changes
in anti-hypertensive medication, home BPmonitoring and 24-h Ambu-
latory BP. The primary safety objectivewas to characterize the rate of se-
rious procedural and device related adverse events through 6 months
post-procedure, as adjudicated by a Clinical Events Committee (CEC).
Additional objectives that will be assessed and reported include but
are not limited to characterization of: the change in Ambulatory Blood
Pressure parameters over time as compared to baseline, renovascular
safety as measured by new renal artery stenosis or aneurysm at the
site of ablation over time as compared to baseline, and renal function
change based on eGFR over time as compared to baseline.
2.9. Study oversight
An independent Clinical Events Committee (CEC) adjudicated all ad-
verse events for relatedness and severity. The corresponding author and
Steering Committee members had full access to the study data.
2.10. Statistical analyses
All continuous variables were summarized using mean, median,
standard deviation (SD) and range. Normality of data was veriﬁed
with the use of box plots and Kolmogorov–Smirnov normality test. For
normally distributed data, comparisons of primary and secondary
outcomes between time points were analyzed using paired t tests.
In cases where the data was not normally distributed the non-
parametric Wilcoxon Signed-Rank test was used to analyze the data.
All categorical variables were summarized using frequencies and
percentages. Statistical analyses were performed using SAS 9.3 (by
SAS Institute Inc., Cary, NC, USA). Statistical signiﬁcance was achieved
if a two-sided test obtained a p value b 0.05.
3. Results
The study enrollment was conducted from April 2013 until August
2013. A total of 65 patients were consented for enrollment and
underwent screening, of which 26 patients were excluded, mainly due
to failure to continue to meet the BP enrollment criteria, the presence
Table 2
Summary of serious adverse events related to the procedure.
Adverse event Number of events Number of patients (%)
Access site pseudoaneurysm 1 1 (2.6%)
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atherosclerosis as deﬁned in the protocol. Thereafter, 39 patients
completed baseline evaluation and were scheduled for the renal dener-
vation procedure.
Baseline demographic, clinical condition, and medication data for
the 39 patients are presented in Table 1. All 39 patients successfully
underwent renal denervation. The median procedure time from initia-
tion to completion of RF energy delivery was 13 min and the mean ±
SD number of ablations delivered was 7.85 ± 0.49 for the right and
8.00±0.69 for the left renal arteries. Thus, the total number of ablations
was 15.85±1.01 and thiswas deliveredwith amean of 4.33±0.62 sets
of treatments.
3.1. Safety results
All adverse eventswere collected in the study. A CEC adjudicated the
events for seriousness and relatedness to the procedure and device. A
complete listing of serious and non-serious procedure and/or device re-
lated adverse events as adjudicated by the CEC is presented in Tables 2
and 3. There were no deaths or unanticipated adverse device effects re-
ported in the trial.
Through sixmonths of follow-up, therewere no serious device relat-
ed adverse events during the procedure, including no renal artery dam-
age (i.e. no renal artery dissections, aneurysms, ﬂow limiting renal
artery vasospasms, or renal artery stenosis). Therewas one reported se-
rious vascular access site complication (pseudoaneurysm of the femoral
artery) which resolved after manual compression and thrombinTable 1
Baseline characteristics (n = 39).
Variable Mean ± SD (min, median, max)
or n (%)
Age (year) 63.49 ± 8.75 (42.0, 65.0, 78.0)
BMI (kg/m2) 31.92 ± 5.17 (20.7, 31.7, 48.1)
Gender (female) 15 (38.5%)
Coronary artery disease 6 (15.4%)
Hyperlipidemia 23 (59.0%)
Diabetes type II 13 (33.3%)
Obstructive sleep apnea 5 (12.8%)
eGFR (mL/min/1.73 m2) 73.97 ± 16.78 (46.0, 76.0, 110.0)
Serum Creatinine (μmol/L) 88.90 ± 19.39 (51.0, 87.0, 142.0)
Cystatin C (mg/L) 1.03 ± 0.30 (0.6, 1.0, 1.9)
Urine Albumin-to-Creatinine ratio (mg/g) 306.53 ± 841.90 (2.7, 32.4, 3996)




Average ofﬁce diastolic blood
pressure (mm Hg)
92.90 ± 14.99 (56.0, 94.0, 125.0)
Average ofﬁce heart rate (BPM) 67.67 ± 15.58 (43.0, 67.0, 107.0)
Average daytime systolic ABP (mm Hg) 158.72 ± 14.02
(138.0, 155.0, 200.0)
Average daytime diastolic ABP (mm Hg) 84.77 ± 12.46 (58.0, 86.0, 108.0)
Average daytime heart rate (BPM) 65.54 ± 14.19 (45.0, 63.0, 110.0)
Average night-time systolic ABP (mm Hg) 146.41 ± 16.16
(112.0, 148.0, 188.0)
Average night-time diastolic ABP (mm Hg) 75.92 ± 12.46 (54.0, 76.0, 102.0)
Average night-time heart rate (BPM) 61.79 ± 12.41 (39.0, 60.0, 92.0)
Average 24 h systolic ABP (mm Hg) 154.85 ± 15.63
(121.0, 152.0, 200.0)
Average 24 h diastolic ABP (mm Hg) 82.08 ± 12.25 (58.0, 83.0, 105.0)
Average 24 h heart rate (BPM) 64.74 ± 13.72 (44.0, 63.0, 110.0)
Number of anti-hypertensive medications 4.67 ± 1.11 (3.0, 5.0, 7.0)
Patients taking the following medications:
Aldosterone antagonists 11 (28.2%)
Alpha adrenergic blockers 16 (41.0%)
Angiotensin converting enzyme inhibitors 20 (51.3%)
Angiotensin receptor blockers 26 (66.7%)
Beta blockers 26 (66.7%)
Calcium channel blockers 30 (76.9%)
Centrally acting sympatholytics 14 (35.9%)
Diuretics 33 (84.6%)
Nitrates 2 (5.1%)
Vasodilators 1 (2.6%)injection. This event extended hospitalization by 24 h but has resolved
without further sequelae. A number of minor peri-procedural events
were noted without further clinical sequelae (Table 3).
Furthermore, there were no serious device related adverse events as
independently adjudicated throughout the 6 month follow-up.
Renal artery evaluationwas conducted on all patients at 6months by
CT imaging, or by ultrasound if contraindicated for a CT. No patients de-
veloped a new hemodynamically signiﬁcant renal artery stenosis.
Renal function was evaluated by repeated measurements of eGFR,
Serum Creatinine, and Cystatin C from baseline through 6 months of
follow-up. No patient experienced a reduction in eGFR N50%, a two-
fold increase in Serum Creatinine, or progressed to end stage renal dis-
ease. There were no statistically or clinically signiﬁcant changes in eGFR
or Creatinine at 6 months post-procedure versus baseline, attesting to
the renal safety of the procedure. The eGFR (mL/min/1.73 m2) values
were baseline 74.0 ± 16.8 (n = 38), 1-month 75.9 ± 15.7 (n = 39),
3-months 73.7 ± 16.4 (n = 38) and 6-months 73.8 ± 17.4 (n = 37)
(6-months p = 0.7075). The Serum Creatinine (μmol/L) values were
baseline 88.9 ± 19.4 (n = 39), 1-month 86.7 ± 21.2 (n = 39), 3-
months 88.2 ± 24.4 (n = 38) and 6-months 88.3 ± 26.2 (n = 37) (6-
months p = 0.7062). Furthermore, there were no clinically signiﬁcant
changes in Cystatin C levels (mg/L, a renal injury marker): baseline
1.03 ± 0.30 (n = 37), 1-month 1.01 ± 0.28 (n = 39), 3-months
1.04 ± 0.28 (n = 35) and 6-months 1.09 ± 0.30 (n = 37) (6-months
p = 0.0393).
TheUrine Albumin-to-Creatinine ratio decreased at 6months versus
baseline although this did not reach statistical signiﬁcance. The mean
Urine Albumin-to-Creatinine ratio values were baseline 306.5 ± 841.9
with median 32.4 mg/g (n = 36), 1-month 230.2 ± 659.0 with
median 27.0 mg/g (n = 36), 3-months 106.0 ± 234.2 with median
21.2 mg/g (n = 33) and 6-months 274.6 ± 613.2 with median
25.6 mg/g (n = 31) (6-months p = 0.4809).
3.2. Efﬁcacy results
Compared to baseline, Ofﬁce and Ambulatory Systolic BP of the cohort
signiﬁcantly decreased at all time points (p values ≤ 0.0030). The average
Ofﬁce BP (mm Hg) at baseline was 174/93 (mm Hg). The resulting aver-
age Ofﬁce BP reductions from baseline were: 1-month−19/−7 mmHg,Table 3
Summary of non-serious adverse events related to procedure or device.
Adverse event Number of events Number of patients (%)
Access site bleeding 1 1 (2.6%)
Access site bruise 9 9 (23.1%)
Access site drainage 5 5 (12.8%)
Access site hematoma 11 10 (25.6%)
Access site pain 3 3 (7.7%)
Arterial hypertension/hypertension 1 1 (2.6%)
Back pain 4 4 (10.3%)
Emesis/vomiting 2 2 (5.1%)
Fever 1 1 (2.6%)
Headache 1 1 (2.6%)
Heartburn 1 1 (2.6%)
Hypotension 6 5 (12.8%)
Kidney pain/ﬂank pain 3 3 (7.7%)
Low back pain 2 2 (5.1%)
Nausea 2 2 (5.1%)
Pain 2 2 (5.1%)
Vaso vagal response 1 1 (2.6%)
Vasospasm 4 4 (10.3%)
Total 59 30 (76.9%)
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(Fig. 3). With regards to responder rates using a deﬁnition of a reduction
in ofﬁce systolic BP of at least 10 mmHg or greater, rates were as follows
1-month—67% (n=26/39), 3-months—82% (n=31/38) and6-months
— 81% (n = 30/37). In addition, by 6 months, over one-third of patients
are now controlled (b140 mm Hg systolic) and the majority are
b160 mm Hg (Fig. 4).
In addition, in-ofﬁce resting heart rate was collected at baseline
67.7 ± 15.6 (n = 39) bpm, 1-month 65.0 ± 14.5 (n = 39), 3-months
65.5 ± 15.9 (n = 38), and 6-months 66.0 ± 14.8 (n = 37).
The average 24-hAmbulatory BP at baselinewas155/82mmHg. The
average 24-h Ambulatory BP (mmHg) reduction from baselinewere, 1-
month −7/−4 mm Hg, 3-months −10/−3 mm Hg and 6-months
−8/−2 mm Hg (p ≤ 0.0030 for systolic changes) (Fig. 5).
Fig. 6 shows average ofﬁce BP, 24-h ABPM, and daytime ABPMmea-
sures at baseline and at 1, 3, and 6months post-procedure. Both systolic
and diastolic valuesmeasured in the ofﬁce or by ambulatorymonitoring
were consistent, exhibiting reductions at 1-month and remaining stable
through 6-months post-procedure.
Over the 6month follow-upperiod, 15/37 subjects (41%) had chang-
es to their anti-hypertension medications: nine patients had a decrease
in their number of anti-hypertensive medications or doses and six had
an increase in their number of anti-hypertensive medications or doses.
For patients that did not have an increase or decrease in their number
of anti-hypertensive medications or doses (n = 22) the 6 month
ofﬁce blood pressure reduction was similar to the entire cohort at
−23/−6 mm Hg (p-values ≤ 0.0006) as well as 24-h ABPM reductions
of−8/−3 mm Hg (p-values: 0.0025, 0.0738).
4. Conclusions
4.1. Discussion
This data demonstrates that the next generation EnligHTN renal de-
nervation system is safe and effective in the treatment of patients with
drug-resistant hypertension. This is evidenced by the absence of serious
device or procedure related adverse events affecting the renal arteries
or renal function throughout the primary endpoint of 6 months of
follow-up and the presence of a statistically and clinically signiﬁcant
−25/−7 mm Hg reduction in ofﬁce BP at 6 months.
The safety data from this study are excellent and add to the growing
body of data regarding the safety of this technique. In the SYMPLICITY
HTN-1 trial one patient had a renal artery dissection and this low fre-
quency has been described in other datasets [8]. Furthermore, renal ar-
tery stenosis is a described phenomenon occurring in approximately 2%
of patients after renal artery denervation in early trials [8,9]. The ab-
sence of any of these serious adverse events in this study warrantsFig. 3. Ofﬁce blood pressure rdiscussion. Although possible that it is simply chance given the sample
size tested, it is worth noting that this study was performed by experi-
enced operators all of whom had prior renal denervation experience
with most having speciﬁc experience with the EnligHTN catheter and
system. In addition, the EnligHTN catheter requires less manipulation
which may reduce the risk of renal artery injury. Also, the fact that all
patients enrolled were able to undergo renal denervation in both renal
arteries is evidence of both the selection process and the procedural
performance.
The efﬁcacy seen in this study is commensurate with that seen in
other published studies, including the EnligHTN I study, and conﬁrms
the consistency of this therapy in experienced hands [9,10]. The lesser
reduction in ofﬁce systolic BP at 1-month than was seen at 3- and 6-
months is consistent with many other studies of renal denervation, al-
though different than what was seen in the EnligHTN I study [8–10].
There is no clear explanation for this difference, however we should
be careful to speculate too broadly given the small sample size. Howev-
er, looking at the datasets ofﬁrst-in-human trials of renal denervation to
date, generally there is a lesser blood pressure reduction at 1-month
that appears to be numerically greater at the 6-month time point [8,10].
The efﬁciency and speed of thenext generation systemcanbedirect-
ly compared with the ﬁrst generation EnligHTN system, and indirectly
with those of other systems. Indeed in this study, the time taken to per-
form the procedure, the time spent with the renal denervation catheter
in situ in the renal arteries, were all less that for the ﬁrst generation
EnligHTN system. In particular, the median time from initiation to
completion of RF energy delivery was reduced by more than half with
the next generation system versus the ﬁrst system (13 min versus
34 min). This provides evidence for potentially improved work-ﬂows
in the Cath lab and potentially would impact cost-effectiveness analyses
for the technique. More than this, though, is the potential that the
shorter procedural times played some role in the excellent safety seen
in this study. The marked reduction in the time of renal artery instru-
mentation required to perform the entire renal denervation procedure
may have been a factor in the absence of serious device related adverse
events seen in this study.
Further issues remain about the best deﬁnition of responder and
whether this is an ofﬁce or ABP index and at what time point it should
be considered. Datasets have shown increased responder rates at the
24-month time-point and beyond [13]. This may be more reﬂective of
additional therapies or other changes, rather than the index renal de-
nervation event however. Clearly further data and focused study is re-
quired to better understand patient and procedural predictors of
response to renal denervation.
This is a single arm, observational ﬁrst-in-human study. Although
the efﬁcacy signal seen is consistent with many other such trials, it is
not a randomized placebo controlled trial. The SYMPLICITY HTN-3 trialeduction from baseline.
Fig. 4. Ofﬁce systolic blood pressure reduction rates.
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failed to show that renal denervation with the SYMPLICITY catheter
was superior to sham control for the purpose of reducing ofﬁce BP at 6
months [12]. Many factors may be suggested to explain this lack of ben-
eﬁt, including the limited number of lesions created, raising the ques-
tion of the adequacy of the renal denervation procedure. For example,
the mean number of lesions in HTN-3 was 9.2 versus 15.9 in this
study. There are also some potential concerns around the geographic lo-
cation of lesions with a single-electrode system that are solved with a
geometrically pre-speciﬁed electrode array of the EnligHTN system.
However, it remains for future studies to prove that next generation
multielectrode renal denervation systems are superior to appropriate
placebo based comparator arms. This study is therefore very important
in this context as it sets the benchmark from a safety and efﬁcacy per-
spective for the EnligHTN systemwithwhich to undertake such a study.
4.2. Summary
Primary results from the second generation EnligHTN system, which
permits simultaneous delivery of all four electrodes, demonstrates the
new system is both safe and effective in the treatment of patients with
resistant hypertension. Future studies will need to address the utility
of this system against an appropriate placebo based comparator.
Novelty and signiﬁcance
What is new?
– This is the primary endpoint manuscript of the ﬁrst in human expe-
riencewith a novelmulti-electrode renal artery denervation system.Fig. 5. 24 h ambulatory blood pres– This new system allows simultaneous delivery of radiofrequency
energy to all four electrodes.
– This next generation system with be studied in future randomized
controlled trials
What is relevant?
– This novel renal denervation system in this trial speciﬁcally
addresses patients with drug resistant hypertension.
– In light of the recent publication by Kandzari in Eur Heart J Jan. 2015
highlighting the relationship between number of ablations in the
renal arteries and need for all four quadrants to receive ablations,
this new system addresses many of the potential short comings of
earlier single electrode renal artery denervation systems.
Summary
– The next generation EnligHTN renal; artery denervation system is
safe and efﬁcacious for the treatment of drug resistant hypertension
in this ﬁrst in human experience.
– Future randomized controlled trials with this system are warranted
and planned.
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